Altered Monocyte and Lymphocyte Phenotypes Associated with Pathogenesis and Clinical Efficacy of Progestogen Therapy for Peritoneal Endometriosis in Adolescents

Cells. 2024 Jul 12;13(14):1187. doi: 10.3390/cells13141187.

Abstract

Background: Immunological imbalances characteristic of endometriosis may develop as early as the primary manifestations of the disease in adolescence. Objective: To evaluate subpopulation dynamics of monocytes and lymphocytes in peripheral blood and peritoneal fluid of adolescents with peritoneal endometriosis at diagnosis and after 1-year progestogen therapy. Methods: This study included 70 girls, 13-17 years old, diagnosed laparoscopically with peritoneal endometriosis (n = 50, main group) or paramesonephric cysts (n = 20, comparison group). Phenotypes of monocytes and lymphocytes of the blood and macrophages of the peritoneal fluid were analyzed by flow cytometry at diagnosis and during progestogen therapy. Results: Differential blood counts of CD16+ (p < 0.001) and CD86+ (p = 0.017) monocytes were identified as independent risk factors for peritoneal endometriosis in adolescents. During the treatment, cytotoxic lymphocytes CD56dimCD16bright (p = 0.049) and CD206+ monocytes (p < 0.001) significantly increased while CD163+ monocytes decreased in number (p = 0.017). The CD56dimCD16bright blood counts before (p < 0.001) and during progestogen therapy (p = 0.006), as well as CD206+ blood counts during the treatment (p = 0.038), were associated with the efficacy of pain relief after 1-year progestogen therapy. Conclusions: Adolescents with peritoneal endometriosis have altered counts of pro- and anti-inflammatory monocytes and lymphocytes both before and after 1-year progestogen therapy, correlating with treatment efficacy and justifying long-term hormonal therapy.

Keywords: CD16; CD163; CD206; CD56; CD86; NK cells; adolescents; endometriosis; lymphocyte; macrophage; pelvic pain; sVEGFR.

MeSH terms

  • Adolescent
  • Ascitic Fluid
  • Endometriosis* / drug therapy
  • Endometriosis* / pathology
  • Female
  • Humans
  • Lymphocytes* / drug effects
  • Lymphocytes* / metabolism
  • Monocytes* / drug effects
  • Monocytes* / metabolism
  • Phenotype*
  • Progestins* / pharmacology
  • Progestins* / therapeutic use
  • Treatment Outcome

Substances

  • Progestins